Share on StockTwits

Celgene (NASDAQ:CELG) has received an “A” credit rating from analysts at Morningstar. The firm’s “A” rating suggests that the company is a low default risk. They also issued a neutral credit outlook for the company and gave their stock a two star rating.

CELG has been the subject of a number of other recent research reports. Analysts at Deutsche Bank reiterated a “buy” rating on shares of Celgene in a research note on Tuesday, August 26th. Separately, analysts at RBC Capital raised their price target on shares of Celgene from $95.00 to $100.00 in a research note on Wednesday, August 6th. They now have an “outperform” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Celgene in a research note on Monday, July 28th. They now have a $92.00 price target on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and fourteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $97.00.

Shares of Celgene (NASDAQ:CELG) opened at 94.94 on Thursday. Celgene has a 52-week low of $66.85 and a 52-week high of $96.44. The stock has a 50-day moving average of $89.12 and a 200-day moving average of $80.53. The company has a market cap of $75.905 billion and a P/E ratio of 54.97.

Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, July 24th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.01. The company had revenue of $1.87 billion for the quarter, compared to the consensus estimate of $1.85 billion. During the same quarter in the prior year, the company posted $1.52 earnings per share. The company’s quarterly revenue was up 17.1% on a year-over-year basis. On average, analysts predict that Celgene will post $3.67 earnings per share for the current fiscal year.

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

To view more credit ratings from Morningstar, visit www.morningstar.com.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.